SCYNEXIS, Inc. Enters into Worldwide Agreement with Waterstone Pharmaceutical for the Development and Commercialization
SCYNEXIS, Inc. Enters into Worldwide Agreement with Waterstone Pharmaceutical for the Development and Commercialization of SCY-635 for Viral Diseases
2014
2013

Waterstone is an international bio-pharmaceutical company committed to the discovery, development and commercilization of therapeutics for significant unmet medical needs

Mobile ScanúČLearn more
About
Company Profile
Management Team
Vision & Mission
Capability
Capability
Advantage
Products
APIs
Intermediates
Highly Potent ADC Drugs
News
Company News
Media Reports
Publications
Contacts
Location & massage
Career